CEA-Scan gets approvable letter from FDA

Article

It's been a long road back for monoclonal antibody developer Immunomedicsand its CEA-Scan imaging agent, but the end is finally in sight.The Morris Plains, NJ, company reported this month that the Foodand Drug Administration has issued an approvable

It's been a long road back for monoclonal antibody developer Immunomedicsand its CEA-Scan imaging agent, but the end is finally in sight.The Morris Plains, NJ, company reported this month that the Foodand Drug Administration has issued an approvable letter for theagent.

CEA-Scan's path through the FDA's regulatory maze was entangledin 1994 when the agency issued a non-approvable letter for thecolorectal cancer imaging agent. Immunomedics worked with theagency to bring CEA-Scan's product license application (PLA) intoa form that FDA reviewers could accept, and an FDA panel recommendedapproval of the product in February (SCAN 2/28/96).

Final marketing approval for CEA-Scan is now subject mainlyto product labeling, Immunomedics said. Immunomedics has assignedU.S. marketing rights for the agent to Mallinckrodt Medical (SCAN4/10/96).

Recent Videos
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
Related Content
© 2025 MJH Life Sciences

All rights reserved.